[Hypoglycemic risk of insulinotropic drugs].
Orally available insulinotropics that directly close K(ATP)-channels, such as sulfonylureas and glinides, differ in their pharmacokinetics and -dynamics (PK/PD). This results in different risks for their incidence of hypoglycemic episodes. Glibenclamide (USAN: glyburide) has the highest risk, followed by glimepiride. Glinides reveal a low risk of hypoglycemia due to their short duration of drug effect. Apart from PK/PD, clinically more relevant factors determine incidences of hypoglycemia. Adequate supervision at initial prescription or switch of insulinotropic drugs, comedication and patient compliance superimpose these pharmacological differences.
Böhm
Ruwen
R
Institut für Experimentelle und Klinische Pharmakologie, Hospitalstrasse 4, 24105 Kiel.
Cascorbi
Ingolf
I
Herdegen
Thomas
T
D001786:Blood Glucose / Q000378:metabolism; D005905:Glyburide / Q000009:adverse effects; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000453:epidemiology*; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D012306:Risk; D013453:Sulfonylurea Compounds / Q000009:adverse effects
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; C057619:glimepiride; D005905:Glyburide